Search Results - "Aarnoutse, R"

Management of patients with multidrug-resistant tuberculosis by Lange, C., Aarnoutse, R. E., Alffenaar, J. W. C., Bothamley, G., Brinkmann, F., Costa, J., Chesov, D., van Crevel, R., Dedicoat, M., Dominguez, J., Duarte, R., Grobbel, H. P., Günther, G., Guglielmetti, L., Heyckendorf, J., Kay, A. W., Kirakosyan, O., Kirk, O., Koczulla, R. A., Kudriashov, G. G., Kuksa, L., van Leth, F., Magis-Escurra, C., Mandalakas, A. M., Molina-Moya, B., Peloquin, C. A., Reimann, M., Rumetshofer, R., Schaaf, H. S., Schön, T., Tiberi, S., Valda, J., Yablonskii, P. K., Dheda, K.

“…The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public…”
Get full text

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis by Aarnoutse, R E, Kibiki, G S, Reither, K, Semvua, H H, Haraka, F, Mtabho, C M, Mpagama, S G, van den Boogaard, J, Sumari-de Boer, I M, Magis-Escurra, C, Wattenberg, M, Logger, J G M, Te Brake, L H M, Hoelscher, M, Gillespie, S H, Colbers, A, Phillips, P P J, Plemper van Balen, G, Boeree, M J

“…In a multiple-dose-ranging trial, we previously evaluated higher doses of rifampin in patients for 2 weeks. The objectives of the current study were to…”
Get full text

Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis by Dian, S, Yunivita, V, Ganiem, A R, Pramaesya, T, Chaidir, L, Wahyudi, K, Achmad, T H, Colbers, A, Te Brake, L, van Crevel, R, Ruslami, R, Aarnoutse, R

“…High doses of rifampin may help patients with tuberculous meningitis (TBM) to survive. Pharmacokinetic pharmacodynamic evaluations suggested that rifampin…”
Get full text

Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis by Nijland, H. M. J., Ruslami, R., Suroto, A. Juwono, Burger, D. M., Alisjahbana, B., van Crevel, R., Aarnoutse, R. E.

“…Background. The long duration of the current tuberculosis (TB) treatment is demanding and warrants the development of new drugs. Moxifloxacin shows promising…”
Get full text

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis by Stott, K E, Pertinez, H, Sturkenboom, M G G, Boeree, M J, Aarnoutse, R, Ramachandran, G, Requena-Méndez, A, Peloquin, C, Koegelenberg, C F N, Alffenaar, J W C, Ruslami, R, Tostmann, A, Swaminathan, S, McIlleron, H, Davies, G

“…The objectives of this study were to explore inter-study heterogeneity in the pharmacokinetics (PK) of orally administered rifampicin, to derive summary…”
Get full text

Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis by Alffenaar, J. W. C., van Altena, R., Bökkerink, H. J., Luijckx, G. J., van Soolingen, D., Aarnoutse, R. E., van der Werf, T. S.

“…Moxifloxacin cerebrospinal fluid (CSF) penetration was evaluated by obtaining full plasma and CSF time concentration curves for 4 patients with tuberculous…”
Get full text

First international quality control programme for laboratories measuring antimicrobial drugs to support dose individualization in critically ill patients by Wallenburg, E, Brüggemann, R J, Asouit, K, Teulen, M, de Haan, A F J, Franssen, E J F, Aarnoutse, R E

“…Abstract Objectives International quality control (proficiency testing) programmes are instituted to safeguard the analytical performance of laboratories and…”
Get full text

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis by Dierig, A, Hoelscher, M, Schultz, S, Hoffmann, L, Jarchow-MacDonald, A, Svensson, E M, Te Brake, L, Aarnoutse, R, Boeree, M, McHugh, T D, Wildner, L M, Gong, X, Phillips, Ppj, Minja, L T, Ntinginya, N, Mpagama, S, Liyoyo, A, Wallis, R S, Sebe, M, Mhimbira, F A, Mbeya, B, Rassool, M, Geiter, L, Cho, Y L, Heinrich, N

“…Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved…”
Get full text

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience by PRANGER, A. D, VAN ALTENA, R, AARNOUTSE, R. E, VAN SOOLINGEN, D, UGES, D. R. A, KOSTERINK, J. G. W, VAN DER WERF, T. S, ALFFENAAR, J. W. C

“…Moxifloxacin (MFX) is a powerful second-line anti-tuberculosis (TB) agent, but the optimal dose has not yet been established and long-term safety data are…”
Get full text

Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients by Wyen, C, Fuhr, U, Frank, D, Aarnoutse, RE, Klaassen, T, Lazar, A, Seeringer, A, Doroshyenko, O, Kirchheiner, JC, Abdulrazik, F, Schmeisser, N, Lehmann, C, Hein, W, Schömig, E, Burger, DM, Fätkenheuer, G, Jetter, A

“…This study aimed to quantify the inhibition of cytochrome P450 (CYP3A), CYP2D6, and P‐glycoprotein in human immunodeficiency virus (HIV)‐infected patients…”
Get full text

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children by Savic, RM, Ruslami, R, Hibma, JE, Hesseling, A, Ramachandran, G, Ganiem, AR, Swaminathan, S, McIlleron, H, Gupta, A, Thakur, K, van Crevel, R, Aarnoutse, R, Dooley, KE

“…Pediatric tuberculous meningitis (TBM) is a highly morbid, often fatal disease. Standard treatment includes isoniazid, rifampin, pyrazinamide, and ethambutol…”
Get full text

Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge [Short communication] by VAN INGEN, J, AARNOUTSE, R, DE VRIES, G, BOEREE, M. J, VAN SOOLINGEN, D

“…In an outbreak of multidrug-resistant tuberculosis, the outbreak strain had an Asp516Tyr rpoB gene mutation. Phenotypically, low-level rifampicin (RMP)…”
Get full text

Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients by te Brake, L H M, Ruslami, R, Later-Nijland, H, Mooren, F, Teulen, M, Apriani, L, Koenderink, J B, Russel, F G, Burger, D M, Alisjahbana, B, Wieringa, F, van Crevel, R, Aarnoutse, R E

“…Nutritional status may have a profound impact on the pharmacokinetics of drugs, yet only few data are available for tuberculosis (TB) drugs. As malnutrition…”
Get full text

Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach by Pranger, A D, Alffenaar, J W C, Aarnoutse, R E

“…Fluoroquinolones (FQs) are important drugs to treat drug-resistant tuberculosis. In this review we integrated pharmacokinetic properties (PK) and…”
Get more information

Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography by Verweij-van Wissen, C.P.W.G.M., Aarnoutse, R.E., Burger, D.M.

“…A reversed phase high performance liquid chromatography method was developed for the simultaneous quantitative determination of the nucleoside reverse…”
Get full text

Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment by Stemkens, R., Litjens, C.H.C., Dian, S., Ganiem, A.R., Yunivita, V., van Crevel, R., te Brake, L.H.M., Ruslami, R., Aarnoutse, R.E.

“…•Exposure to pyrazinamide (PZA) in plasma decreases during the initial days of tuberculous meningitis treatment.•PZA penetrates well into cerebrospinal…”
Get full text

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin by Magis-Escurra, C, Later-Nijland, H.M.J, Alffenaar, J.W.C, Broeders, J, Burger, D.M, van Crevel, R, Boeree, M.J, Donders, A.R.T, van Altena, R, van der Werf, T.S, Aarnoutse, R.E

“…Abstract Therapeutic drug monitoring (TDM) of tuberculosis (TB) drugs currently focuses on peak plasma concentrations, yet total exposure [area under the 24-h…”
Get full text

Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations by Lempers, V J C, Alffenaar, J W C, Touw, D J, Burger, D M, Uges, D R A, Aarnoutse, R E, Brüggemann, R J M

“…Since 2007 the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring (KKGT) has organized an international interlaboratory proficiency…”
Get full text

Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique by van Boekel, G. A. J., Donders, A. R. T., Hoogtanders, K. E. J., Havenith, T. R. A., Hilbrands, L. B., Aarnoutse, R. E.

“…Purpose The aim of this study was to develop a clinically applicable limited sampling strategy for ambulatory Caucasian kidney transplant patients to estimate…”
Get full text

Pharmacokinetics of anti‐tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations by Verhagen, L. M., López, D., Hermans, P. W. M., Warris, A., de Groot, R., García, J. F., de Waard, J. H., Aarnoutse, R. E.

“…Objectives  The World Health Organization (WHO) recently issued revised first‐line antituberculosis (anti‐TB) drug dose recommendations for children, with dose…”
Get full text